Street Research

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Edwards Lifesciences price target raised to $133 from $123 at Piper Sandler » 19:16
12/08/21
12/08
19:16
12/08/21
19:16
EW

Edwards Lifesciences

$119.46 /

+3.99 (+3.46%)

Piper Sandler analyst…

Piper Sandler analyst Adam Maeder raised the firm's price target on Edwards Lifesciences to $133 from $123 and keeps an Overweight rating on the shares. The analyst said the company's guidance for FY21 and FY22, as well as its pipeline updates, lay the foundation for long-term growth. Maeder added that he continues to view Edwards as a differentiated large-cap medtech growth name with a "compelling" and durable financial profile.

ShowHide Related Items >><<
EW Edwards Lifesciences
$119.46 /

+3.99 (+3.46%)

EW Edwards Lifesciences
$119.46 /

+3.99 (+3.46%)

12/06/21 Wells Fargo
Wells Fargo upgrades Edwards Lifesciences to Overweight on pipeline catalysts
12/06/21 Wells Fargo
Edwards Lifesciences upgraded to Overweight from Equal Weight at Wells Fargo
11/30/21 Piper Sandler
Edwards Lifesciences positioned as 'beat-and-raise story,' says Piper Sandler
10/29/21 Jefferies
Edwards Lifesciences price target raised to $135 from $130 at Jefferies
EW Edwards Lifesciences
$119.46 /

+3.99 (+3.46%)

EW Edwards Lifesciences
$119.46 /

+3.99 (+3.46%)

EW Edwards Lifesciences
$119.46 /

+3.99 (+3.46%)

Downgrade
Dicerna downgraded to Neutral from Buy at Chardan » 19:12
12/08/21
12/08
19:12
12/08/21
19:12
DRNA

Dicerna

$38.01 /

-0.165 (-0.43%)

Chardan analyst Keay…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DRNA Dicerna
$38.01 /

-0.165 (-0.43%)

DRNA Dicerna
$38.01 /

-0.165 (-0.43%)

11/22/21
Fly Intel: Top five analyst downgrades
11/22/21 Stifel
Dicerna downgraded to Hold from Buy at Stifel
11/19/21 RBC Capital
Dicerna downgraded to Sector Perform from Outperform at RBC Capital
11/19/21 RBC Capital
Dicerna downgraded to Sector Perform from Outperform at RBC Capital
DRNA Dicerna
$38.01 /

-0.165 (-0.43%)

DRNA Dicerna
$38.01 /

-0.165 (-0.43%)

Initiation
Traton reinstated with a Neutral at Goldman Sachs » 18:57
12/08/21
12/08
18:57
12/08/21
18:57
TRATF

Traton

$24.93 /

+ (+0.00%)

Goldman Sachs analyst…

Goldman Sachs analyst Daniela Costa reinstated coverage of Traton with a Neutral rating and EUR 23 price target. The analyst said the deal with Navistar gives Traton a balanced regional global profile, closer to that of other leading OEMs. Costa noted, however, that the stock has underperformed the firm's European Capital Goods coverage since its 2019 listing, though it currently trades at a discount to both the capital goods sector and trucking peers.

ShowHide Related Items >><<
TRATF Traton
$24.93 /

+ (+0.00%)

11/01/21 Deutsche Bank
Traton price target lowered to EUR 30 from EUR 33 at Deutsche Bank
10/05/21 Deutsche Bank
Traton price target lowered to EUR 33 from EUR 35 at Deutsche Bank
07/02/21 UBS
Traton price target raised to EUR 30 from EUR 29 at UBS
06/25/21 Barclays
Traton price target raised to EUR 34 from EUR 33 at Barclays
Downgrade
Allstate downgraded to Underweight from Equal Weight at Wells Fargo » 17:29
12/08/21
12/08
17:29
12/08/21
17:29
ALL

Allstate

$109.02 /

-1.22 (-1.11%)

Wells Fargo analyst Elyse…

Wells Fargo analyst Elyse Greenspan downgraded Allstate to Underweight from Equal Weight.

ShowHide Related Items >><<
ALL Allstate
$109.02 /

-1.22 (-1.11%)

ALL Allstate
$109.02 /

-1.22 (-1.11%)

11/22/21 Goldman Sachs
Allstate initiated with a Sell at Goldman Sachs
11/18/21 Jefferies
Jefferies starts Allstate at Hold, sees inflation as key focal point for sector
11/18/21 Jefferies
Allstate initiated with a Hold at Jefferies
11/10/21
Fly Intel: Top five analyst downgrades
ALL Allstate
$109.02 /

-1.22 (-1.11%)

ALL Allstate
$109.02 /

-1.22 (-1.11%)

Upgrade
Phillips 66 upgraded to Overweight from Neutral at JPMorgan » 17:06
12/08/21
12/08
17:06
12/08/21
17:06
PSX

Phillips 66

$71.84 /

-0.64 (-0.88%)

JPMorgan analyst Phil…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PSX Phillips 66
$71.84 /

-0.64 (-0.88%)

PSX Phillips 66
$71.84 /

-0.64 (-0.88%)

11/15/21 Wells Fargo
Phillips 66 price target raised to $104 from $97 at Wells Fargo
11/03/21 Goldman Sachs
Phillips 66 upgraded to Conviction Buy from Buy at Goldman Sachs
11/01/21 Raymond James
Phillips 66 Partners downgraded to Market Perform from Outperform at Raymond James
10/28/21 Credit Suisse
Credit Suisse cuts Phillips 66 Partners to Neutral on acquisition announcement
PSX Phillips 66
$71.84 /

-0.64 (-0.88%)

PSX Phillips 66
$71.84 /

-0.64 (-0.88%)

PSX Phillips 66
$71.84 /

-0.64 (-0.88%)

PSX Phillips 66
$71.84 /

-0.64 (-0.88%)

Downgrade
Uniper downgraded to Hold from Buy at Nord/LB » 16:38
12/08/21
12/08
16:38
12/08/21
16:38
UNPRF

Uniper

$42.28 /

+ (+0.00%)

Nord/LB analyst Holger…

Nord/LB analyst Holger Fechner downgraded Uniper to Hold from Buy with a EUR 40 price target.

ShowHide Related Items >><<
UNPRF Uniper
$42.28 /

+ (+0.00%)

12/02/21 Deutsche Bank
Uniper price target raised to EUR 41 from EUR 40 at Deutsche Bank
11/12/21 RBC Capital
Uniper price target raised to EUR 35 from EUR 33 at RBC Capital
11/02/21 Deutsche Bank
Uniper price target raised to EUR 40 from EUR 39 at Deutsche Bank
10/26/21 Oddo BHF
Uniper downgraded to Underperform from Neutral at Oddo BHF
Initiation
Eli Lilly initiated with an Equal Weight at Wells Fargo » 16:35
12/08/21
12/08
16:35
12/08/21
16:35
LLY

Eli Lilly

$244.28 /

-0.77 (-0.31%)

Wells Fargo analyst Mohit…

Wells Fargo analyst Mohit Bansal initiated coverage of Eli Lilly with an Equal Weight rating and $270 price target. The company has a "solid growth business and clean story otherwise," but its Alzheimer's prospects will likely dominate 2022, Bansal tells investors in a research note. The analyst says that according to his experts, early approval of donanemab would be less important long term. This, coupled with Eli Lilly's valuation, keeps him on the sidelines.

ShowHide Related Items >><<
LLY Eli Lilly
$244.28 /

-0.77 (-0.31%)

LLY Eli Lilly
$244.28 /

-0.77 (-0.31%)

11/30/21 Canaccord
Sigilon Therapeutics price target lowered to $12 from $23 at Canaccord
11/29/21 Morgan Stanley
Morgan Stanley, assuming Omicron becomes dominant, ups Adagio to Overweight
11/24/21 Truist
Eli Lilly price target raised to $301 from $262 at Truist
11/18/21 BMO Capital
Eli Lilly initiated with an Outperform at BMO Capital
LLY Eli Lilly
$244.28 /

-0.77 (-0.31%)

LLY Eli Lilly
$244.28 /

-0.77 (-0.31%)

LLY Eli Lilly
$244.28 /

-0.77 (-0.31%)

LLY Eli Lilly
$244.28 /

-0.77 (-0.31%)

Initiation
Gilead initiated with an Equal Weight at Wells Fargo » 16:33
12/08/21
12/08
16:33
12/08/21
16:33
GILD

Gilead

$69.72 /

+0.04 (+0.06%)

Wells Fargo analyst Mohit…

Wells Fargo analyst Mohit Bansal initiated coverage of Gilead Sciences with an Equal Weight rating and $72 price target. The company's cancer expansion is going well and Trodelvy will likely work in the TROPiCS-02 trial, but this may already be priced in, Bansal tells investors in a research note. The analyst says Gilead's HIV business "appears to be slowing down" and that its post-pandemic recovery "may not be enough to propel it back to double-digit growth."

ShowHide Related Items >><<
GILD Gilead
$69.72 /

+0.04 (+0.06%)

GILD Gilead
$69.72 /

+0.04 (+0.06%)

12/07/21 Piper Sandler
Gilead's lenacapavir opportunity remains intact, says Piper Sandler
12/06/21 Goldman Sachs
Gilead initiated with a Neutral at Goldman Sachs
11/19/21 Barclays
Arcus Biosciences price target raised to $60 from $48 at Barclays
11/18/21 BMO Capital
Gilead upgraded to Outperform from Market Perform at BMO Capital
GILD Gilead
$69.72 /

+0.04 (+0.06%)

GILD Gilead
$69.72 /

+0.04 (+0.06%)

GILD Gilead
$69.72 /

+0.04 (+0.06%)

GILD Gilead
$69.72 /

+0.04 (+0.06%)

Initiation
Oppenheimer starts Benson Hill at Outperform citing protein consumption trends » 16:32
12/08/21
12/08
16:32
12/08/21
16:32
BHIL

Benson Hill

$7.25 /

+0.22 (+3.13%)

Oppenheimer analyst…

Oppenheimer analyst Kristen Owen initiated coverage of Benson Hill with an Outperform rating and $9 price target. The analyst notes that Benson Hill seeks to "deliver higher value for producers through de-commoditization," starting with yellow pea and ultra-high-protein soybeans, and believes that the company, levered to protein consumption trends, "can be an important supplier in the rapidly expanding plant- based meat category."

ShowHide Related Items >><<
BHIL Benson Hill
$7.25 /

+0.22 (+3.13%)

BHIL Benson Hill
$7.25 /

+0.22 (+3.13%)

16:13 Today Oppenheimer
Benson Hill initiated with an Outperform at Oppenheimer
11/23/21 Goldman Sachs
Benson Hill initiated with a Neutral at Goldman Sachs
10/25/21 Barclays
Benson Hill initiated with an Overweight at Barclays
BHIL Benson Hill
$7.25 /

+0.22 (+3.13%)

BHIL Benson Hill
$7.25 /

+0.22 (+3.13%)

Initiation
Amgen initiated with an Equal Weight at Wells Fargo » 16:31
12/08/21
12/08
16:31
12/08/21
16:31
AMGN

Amgen

$213.54 /

+2.24 (+1.06%)

Wells Fargo analyst Mohit…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AMGN Amgen
$213.54 /

+2.24 (+1.06%)

AMGN Amgen
$213.54 /

+2.24 (+1.06%)

12/06/21 Goldman Sachs
Amgen initiated with a Buy at Goldman Sachs
11/22/21 Mizuho
Amgen price target lowered to $194 from $222 at Mizuho
11/18/21 BMO Capital
Amgen initiated with a Market Perform at BMO Capital
11/01/21 Oppenheimer
Amgen price target lowered to $272 from $277 at Oppenheimer
AMGN Amgen
$213.54 /

+2.24 (+1.06%)

AMGN Amgen
$213.54 /

+2.24 (+1.06%)

AMGN Amgen
$213.54 /

+2.24 (+1.06%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.